ALZN Stock Analysis: Buy, Sell, or Hold?
ALZN - Alzamend Neuro, Inc. Common Stock
$1.43
0.09 (6.72%)
▲
5d:
+9.16%
30d:
+23.28%
90d:
+28.83%
HOLD
MODERATE Confidence
Analysis Updated: Aug 3, 2026 12:00 AM ET
Earnings: Sep 09, 2026
Get Alerted When ALZN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: ALZN is 7.5% above its trading range ($1.33). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: ALZN is 7.5% above its trading range ($1.33). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: ALZN is currently trading at $1.43, which is considered extended relative to its 30-day fair value range of $1.16 to $1.33.
Technical Outlook: Technically, ALZN is in a downtrend. The price is approaching resistance at $1.38. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 6.7% recently.
Market Sentiment: ALZN has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $25.00 (+1765.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ALZN is in a downtrend. The price is approaching resistance at $1.38. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 6.7% recently.
Market Sentiment: ALZN has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $25.00 (+1765.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.16 -
$1.33
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range (+7.5% above its trading range)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+6.7%)
- BULLISH: Trading 1765.7% below Wall St target ($25.00)
- CAUTION: Extended 7.5% above its trading range - wait for pullback
Trading Range Analysis
30-Day Trading Range
$1.16 -
$1.33
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.21
Resistance Level
$1.38
Current Trend
Downtrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.52
Wall Street Target
$25.00
(+1765.7%)
Share & Embed Analysis
Last updated: August 04, 2026 1:44 PM ET
Data refreshes hourly during market hours. Next update: 2:44 PM
Data refreshes hourly during market hours. Next update: 2:44 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ALZN showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Milton C Ault III
BUY
108388 shares
2026-04-14
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$416 | 51 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$87 | 56 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$196 | 46 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$108 | 60 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 51 HOLD |
